aTYR PHARMA (ATYR) Free Cash Flow Growth (3y) (2017 - 2026)
Powered by 
Analysis
aTYR PHARMA (ATYR) Free Cash Flow Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | -3.13% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 16.01% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | -1.95% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | -20.15% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 21.16% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 80.69% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -0.65% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - | 13.19% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 13.19% |
| Mar 31, 2026 | -90.31% |
| Dec 31, 2025 | -2.10% |
| Sep 30, 2025 | -17.31% |
| Jun 30, 2025 | -14.88% |
| Mar 31, 2025 | -14.91% |
| Dec 31, 2024 | -17.53% |
| Sep 30, 2024 | -4.54% |
| Jun 30, 2024 | -37.98% |
| Mar 31, 2024 | -56.49% |
| Dec 31, 2023 | -27.02% |
| Sep 30, 2023 | -22.03% |
| Jun 30, 2023 | -30.90% |
| Mar 31, 2023 | -43.75% |
| Dec 31, 2022 | -32.34% |
| Sep 30, 2022 | -43.71% |
| Jun 30, 2022 | -23.90% |
| Mar 31, 2022 | -18.98% |
| Dec 31, 2021 | -18.68% |
| Sep 30, 2021 | -21.08% |